Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalised molecularly guided treatment for advanced pancreatic adenocarcinoma
ACTRN12612000777897Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Nov 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, trastuzumab, cisplatin and erlotinib in pancreatic adenocarcinoma (PDAC) (3 cohorts), sponsored by Australasian Gastro-Intestinal Trials Group. Primary endpoint: Technical feasibility. Started Nov 2013; status: completed.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ACTRN12612000777897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000777897.